Doxorubicin, also known as Adriamycin, is an anthracycline drug commonly used in cancer chemotherapy. Adriamycin is being used clinically for solid tumours, e.g. adenocarcinoma of breast, malignant sarcomas, neuroblastoma, ovarian cancer, small lung cancer as well as hematologic malignancies including lymphomas and leukaemias. In this review we can answers different questions from which mainly we focus on that how we can prevent its toxicity and interactions with other agents and which parameters we use for to overcome this. Unfortunately, its therapeutic potential can be limited to cardiotoxicity so for to overcome this liposomal encapsulation of doxorubicin done for to overcome toxicity problems. However its use has been limited by its major clinical side effect, cardiotoxicity. Toxic effect of Adriamycin can be prevented by using different pharmacologic substances like antioxidants. Adriamycin produces its antineoplastic effect by multiple mechanisms and the exact mechanism of action of Adriamycin is still unknown. The proposed mechanism of the antineoplastic effect of Adriamycin at the cellular level is drug binding to DNA by intercalation between base pairs and inhibition of RNA synthesis by template disordering and steric obstruction.
Muhammad Zeeshan Zafar, Huma Sabir
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2018 All rights reserved. iMedPub LTD Last revised : October 18, 2018